Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04726332
Title Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Exelixis

Her2-receptor negative breast cancer

peritoneum cancer

prostate adenocarcinoma

triple-receptor negative breast cancer

ovary epithelial cancer

fallopian tube cancer

Advanced Solid Tumor


Abiraterone + Prednisone + XL102

Fulvestrant + XL102


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.